Gabriel C. Léger

3.2k total citations · 1 hit paper
43 papers, 2.0k citations indexed

About

Gabriel C. Léger is a scholar working on Psychiatry and Mental health, Physiology and Neurology. According to data from OpenAlex, Gabriel C. Léger has authored 43 papers receiving a total of 2.0k indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Psychiatry and Mental health, 13 papers in Physiology and 11 papers in Neurology. Recurrent topics in Gabriel C. Léger's work include Dementia and Cognitive Impairment Research (15 papers), Alzheimer's disease research and treatments (12 papers) and Medical Imaging Techniques and Applications (6 papers). Gabriel C. Léger is often cited by papers focused on Dementia and Cognitive Impairment Research (15 papers), Alzheimer's disease research and treatments (12 papers) and Medical Imaging Techniques and Applications (6 papers). Gabriel C. Léger collaborates with scholars based in United States, Canada and China. Gabriel C. Léger's co-authors include Hector M. González, Albert Gjedde, Hiroto Kuwabara, Mark Guttman, Paul Cumming, Alan C. Evans, Emily Rogalskı, Fadi Massoud, Eileen H. Bigio and Marsel Mesulam and has published in prestigious journals such as Proceedings of the National Academy of Sciences, PLoS ONE and Neurology.

In The Last Decade

Gabriel C. Léger

40 papers receiving 1.9k citations

Hit Papers

align trajectories

Peers

Countries citing papers authored by Gabriel C. Léger

Since Specialization

Citations

This map shows the geographic impact of Gabriel C. Léger's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gabriel C. Léger with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gabriel C. Léger more than expected).

Fields of papers citing papers by Gabriel C. Léger

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Gabriel C. Léger. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gabriel C. Léger. The network helps show where Gabriel C. Léger may publish in the future.

Co-authorship network of co-authors of Gabriel C. Léger

This figure shows the co-authorship network connecting the top 25 collaborators of Gabriel C. Léger. A scholar is included among the top collaborators of Gabriel C. Léger based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Gabriel C. Léger. Gabriel C. Léger is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Prognostic value of plasma biomarkers for informing clinical trial design in mild-to-moderate Alzheimer’s disease 2025 ·Alzheimer s Research & Therapy ·Yuqi Qiu, Diane M. Jacobs, Karen Messer, David P. Salmon, Cheryl L. Wellington, Sophie Stukas, Carolyn Revta, James Brewer, Gabriel C. Léger, (unknown), (unknown), Stephen Kaplita, Vladimir Coric, Irfan Qureshi, Howard Feldman, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown)	0
2	Protocol for a seamless phase 2A-phase 2B randomized double-blind placebo-controlled trial to evaluate the safety and efficacy of benfotiamine in patients with early Alzheimer’s disease (BenfoTeam) 2024 ·PLoS ONE ·Howard Feldman, José A. Luchsinger, Gabriel C. Léger, Curtis Taylor, Diane M. Jacobs, David P. Salmon, Steven D. Edland, Karen Messer, Carolyn Revta, Sarah A. Flowers, Kerry S. Jones, Albert Koulman, Kevin E. Yarasheski, Philip B. Verghese, (unknown), Henrik Zetterberg, (unknown), (unknown), Gary E. Gibson, (unknown)	1
3	Comparison of the telephone‐Montreal Cognitive Assessment (T‐MoCA) and Telephone Interview for Cognitive Status (TICS) as screening tests for early Alzheimer's disease 2023 ·Alzheimer s & Dementia ·(unknown), Christina Gigliotti, Gabriel C. Léger, Guerry M. Peavy, Diane M. Jacobs, Sarah J. Banks, Emily A. Little, Douglas Galasko, David P. Salmon	10
4	Case report: Neuronal intranuclear inclusion disease presenting with acute encephalopathy 2023 ·Frontiers in Neurology ·(unknown), Dolores Torres, (unknown), (unknown), Juan Carlos Vera, (unknown), Anastasie Dunn‐Pirio, Suzan Khoromi, (unknown), Gabriel C. Léger, Joseph D. Ciacci, (unknown), (unknown), David G. Coughlin, (unknown), Nikdokht Farid	1
5	Amygdala sign, a FDG-PET signature of dementia with Lewy Bodies 2019 ·Parkinsonism & Related Disorders ·Jagan A. Pillai, Guiyun Wu, Babak Tousi, Mykol Larvie, Gabriel C. Léger, James B. Leverenz	8
6	Comparing the Electronic and Standard Versions of the Montreal Cognitive Assessment in an Outpatient Memory Disorders Clinic: A Validation Study 2018 ·Journal of Alzheimer s Disease ·(unknown), (unknown), Gabriel C. Léger, Jeffrey L. Cummings, Ziad Nasreddine, Justin B. Miller	43
7	Memory Test Performance on Analogous Verbal and Nonverbal Memory Tests in Patients with Frontotemporal Dementia and Alzheimer's Disease 2016 ·Dementia and Geriatric Cognitive Disorders Extra ·(unknown), Justin B. Miller, Gabriel C. Léger, Sarah J. Banks	6
8	Randomized controlled trials in frontotemporal dementia: cognitive and behavioral outcomes 2014 ·Translational Neurodegeneration ·Justin B. Miller, Sarah J. Banks, Gabriel C. Léger, Jeffrey L. Cummings	17
9	Neuropsychiatric Symptom Profile Differs Based on Pathology in Patients with Clinically Diagnosed Behavioral Variant Frontotemporal Dementia 2013 ·Dementia and Geriatric Cognitive Disorders ·Gabriel C. Léger, Sarah J. Banks	41
10	Novel disease-modifying therapeutics for the treatment of Alzheimer’s disease 2013 ·Expert Review of Clinical Pharmacology ·Gabriel C. Léger, Fadi Massoud	8
11	Rosuvastatin positively changes nerve electrophysiology in diabetic rats 2009 ·Diabetes/Metabolism Research and Reviews ·(unknown), P. Valensi, Gabriel C. Léger, (unknown), (unknown), A Béhar	6
12	Spontaneous mitochondrial membrane potential change during apoptotic induction by quercetin in K562 and K562/adr cells 2004 ·Canadian Journal of Physiology and Pharmacology ·S. Kothan, Nathupakorn Dechsupa, Gabriel C. Léger, Jean‐Luc Moretti, Jackie Vergote, Samlee Mankhetkorn	26
13	Structural Changes Induced by Binding of the High-Mobility Group I Protein to a Mouse Satellite DNA Sequence 2000 ·Biophysical Journal ·Anny Slama‐Schwok, K. Zakrzewska, Gabriel C. Léger, Yves Leroux, (unknown), Emmanuel Käs, Pascale Debey	24
14	Regional striatal DOPA transport and decarboxylase activity in Parkinson's disease. 1995 ·PubMed ·Hiroto Kuwabara, Paul Cumming, Yoshifumi Yasuhara, Gabriel C. Léger, Mark Guttman, Mirko Dikšić, Alan C. Evans, Albert Gjedde	30
15	Correction for partial volume effects in PET using MRI-based 3-D simulations of individual human brain metabolism 1993 ·Annals of Nuclear Medicine ·Olivier Rousset, Yilong Ma, Gabriel C. Léger, Albert Gjedde, Alan C. Evans	22
16	Striatal L‐DOPA Decarboxylase Activity in Parkinson's Disease In Vivo: Implications for the Regulation of Dopamine Synthesis 1993 ·Journal of Neurochemistry ·Albert Gjedde, Gabriel C. Léger, Paul Cumming, Yoshifumi Yasuhara, Alan C. Evans, Mark Guttman, Hiroto Kuwabara	64
17	Human Striatal l-DOPA Decarboxylase Activity Estimated in vivo Using 6-[¹⁸F]fluoro-DOPA and Positron Emission Tomography: Error Analysis and Application to Normal Subjects 1993 ·Journal of Cerebral Blood Flow & Metabolism ·Hiroto Kuwabara, Paul Cumming, Jakob Reith, Gabriel C. Léger, Mirko Dikšić, Alan C. Evans, Albert Gjedde	80
18	3‐O‐methyldopa administration does not alter fluorodopa transport into the brain 1992 ·Annals of Neurology ·Mark Guttman, Gabriel C. Léger, Jesse M. Cedarbaum, Avinoam Reches, William R. Woodward, Alan C. Evans, Mirko Dikšić, Albert Gjedde	34
19	Reduction of Circulating 3-O-Methyldopa by Inhibition of Gatechol-O-Methyltransferase With OR-611 and OR-462 in Cynomolgus Monkeys 1991 ·Clinical Neuropharmacology ·Jesse M. Cedarbaum, Gabriel C. Léger, Mark Guttman	34
20	Effect of Nitecapone (OR-462) on the Pharmacokinetics of Levodopa and 3-O-Methyldopa Formation in Cynomolgus Monkeys 1990 ·Clinical Neuropharmacology ·Jesse M. Cedarbaum, Gabriel C. Léger, Avinoam Reches, Mark Guttman	13

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact